Navigation Links
Emerging Lymphoma and Myeloma Treatments Focus on Improving Individual Patient Response
Date:12/11/2011

n as a possible biomarker to improve treatment and patient outcomes in multiple myeloma," said senior author Keith Stewart, MD, Professor of Medicine in the Division of Hematology-Oncology at Mayo Clinic in Scottsdale, Ariz. "This work also suggests that we can begin to isolate the cause of birth defects from the anti-cancer properties in order to develop safer drugs in the future."

Yuan Xiao Zhu, PhD, will present this study in an oral presentation on Sunday, December 11, at 4:30 p.m. PST at the San Diego Convention Center in Room 6DE.

Final Analysis of a Randomized Comparison of ABVD Chemotherapy with a Strategy that Includes Radiation Therapy (RT) in Patients with Limited-Stage Hodgkin Lymphoma (HL): NCIC CTG/ECOG HD.6 [Abstract 590]

New research concludes that patients with limited-stage Hodgkin lymphoma treated with a standard chemotherapy regimen have better overall survival rates compared with those receiving a radiation-based treatment.

Patients with limited-stage Hodgkin lymphoma (HL) are often treated with combination therapy containing chemotherapy plus radiation (RT). While this therapy is successful in controlling HL, these patients remain challenged by potential long-term complications of radiation exposure such as heart conditions or subsequent cancers.

To determine if HL patients treated with standard chemotherapy (ABVD) have better long-term survival than those treated with radiation-based therapy, researchers from Canada's NCIC Clinical Trials Group (NCIC CTG) designed a trial comparing the 12-year overall survival (OS) between the two groups. The Eastern Cooperative Oncology Group (ECOG) also participated in the trial. Along with overall survival, the trial also examined secondary survival factors, including freedom from disease progression (FFDP) and event-free survival (EFS).

Approximately 400 patients with no
'/>"/>

SOURCE American Society of Hematology
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Established and Emerging Biotech Clusters
2. PAREXEL International to Present at Robert Baird Healthcare Conference and William Blair Emerging Growth Stock Conference
3. Tumor Marker Diagnostic Technologies: Assessment of Current and Emerging Technologies, And Their Potential Market Applications
4. GRAPHENE-CA appointed an EU Future Emerging Technology flagship pilot
5. Reportlinker Adds Top & Emerging Bio-Fuel Markets by Technology, Feedstocks, Regulations, Pricing & Commercialization Trends & Forecasts (2011 - 2016)
6. Reportlinker Adds The 2011 Blood Banking Market: US, Europe, Japan - Emerging Opportunities and Business Expansion Strategies for Suppliers
7. Zimmer Helps Physicians and Hospitals Negotiate Emerging Health Care Business Challenges Through New Consulting Programs
8. Elixir Bio-Tech Inc. Elected One of Top 50 Emerging Companies by 100 Venture Capital Funds & Angel Investors
9. Reportlinker Adds Future US In Vitro Diagnostics Market: Strategic Implications of Emerging Reimbursement, Technological and Market Trends Through 2018
10. Reportlinker Adds The 2011 Coagulation Testing Market: US, Europe, Japan Emerging Business Opportunities and Market Expansion Strategies for Suppliers
11. Reportlinker Adds Emerging Opportunities in Biosimilar and Biobetter Drugs Markets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... PA & Boston, MA (PRWEB) July 28, 2014 ... collaboration agreements with two researchers to further develop potential ... deadly malignant brain tumor, in combination with their patented ... by ITI and Duke University, are based on the ... Chief, Division of Neurosurgery at The Preston Robert Tisch ...
(Date:7/28/2014)... , July 28, 2014  InterMune, Inc. (NASDAQ: ... release its second quarter 2014 financial results at the ... 2014. A live conference call and webcast will be hosted ... day. Interested investors and others may participate ... +1 212-231-2900 (international), conference ID#21728775. A replay of the webcast ...
(Date:7/25/2014)... "Ischemic Stroke and Cerebral Stroke ... on the Ischemic Stroke and Cerebral Stroke clinical ... data relating to the clinical trials on Ischemic ... Ischemic Stroke Research Report 2014 at: http://www.marketresearchreports.biz/analysis/213207 ... trial numbers and their recruitment status as per ...
(Date:7/25/2014)... According to a new market report ... Global Industry Analysis, Size, Share, Growth, Trends and Forecast, ... estimated at USD 161,056.5 million in 2014 and is ... 2014 to 2020, to reach an estimated value of ... market is witnessing a significant growth due to the ...
Breaking Biology Technology:String of Collaborations Launch Immunomic Therapeutics’ Brain Tumor Program Pipeline 2String of Collaborations Launch Immunomic Therapeutics’ Brain Tumor Program Pipeline 3String of Collaborations Launch Immunomic Therapeutics’ Brain Tumor Program Pipeline 4InterMune to Release Second Quarter Financial Results on August 6 2Ischemic Stroke and Cerebral Stroke Global Clinical Trials Review H2, 2014: MarketResearchReports.Biz 2Ischemic Stroke and Cerebral Stroke Global Clinical Trials Review H2, 2014: MarketResearchReports.Biz 3Biological Drugs Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 2Biological Drugs Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 3
... 5 Cell Therapeutics (CTI),(Nasdaq and MTA: CTIC) announced ... Preferred Stock in exchange for 6,634 shares of CTI,s ... constitutes 83% in interest of all,series of CTI,s Convertible ... become convertible into 7,143 shares of CTI,s common stock, ...
... DIEGO, Feb. 4 Orexigen(R) Therapeutics, Inc.,(Nasdaq: OREX ), ... the Company will be speaking at the 11th Annual,BIO CEO & ... Corporate Presentation:, Date: Monday, February 9, ... Eastern, Location: Waldorf Astoria, Astor Room, New York, ...
... Feb. 4 NeurogesX, Inc. (Nasdaq: NGSX ... novel pain management therapies, announced today that Anthony DiTonno, ... at the 11th Annual BIO CEO & Investor Conference ... Mr. DiTonno and Stephen Ghiglieri, Chief Financial Officer, will ...
Cached Biology Technology:Cell Therapeutics Exchanges 83% of Remaining Convertible Preferred Stock Into New Non-dividend Bearing, Non-redeemable Convertible Preferred Stock With Conversion Price of $0.14 per Share 2NeurogesX to Present at 11th Annual BIO CEO & Investor Conference 2NeurogesX to Present at 11th Annual BIO CEO & Investor Conference 3
(Date:7/28/2014)... top 10 U.S. cities that have seen an increase ... frequent road closures, overwhelmed storm drains and compromised infrastructure--are ... technical report. , This nuisance flooding, caused by rising ... between 300 and 925 percent since the 1960s. , ... Changes around the United States, also finds Annapolis and ...
(Date:7/28/2014)... The findings of a new study suggest two ways ... not work as well in obese women, compared to women ... are a one-size-fits-all method, researchers say, but as the population ... the pill works for obese women. Studies have consistently found ... the body, which may in turn affect how well the ...
(Date:7/28/2014)... He calls himself the bug hunter, but the ... only be found and identified with special methods and ... Kansas State Veterinary Diagnostic Laboratory at Kansas State University, ... porcine enterovirus G, which is an important find in ... in cells, but didn,t know what it was," Hause ...
Breaking Biology News(10 mins):NOAA: 'Nuisance flooding' an increasing problem as coastal sea levels rise 2NOAA: 'Nuisance flooding' an increasing problem as coastal sea levels rise 3Strategies identified to improve oral contraceptive success with obese women 2Researcher using next-generation sequencing to rapidly identify pathogens 2Researcher using next-generation sequencing to rapidly identify pathogens 3
... Kan. -- With harvest in full swing, many farmers have ... and minimal rainfall has left most wheat yields looking less ... ugly. But as a Kansas State University plant pathologist ... also has been battling a much smaller opponent: viruses. ...
... to be an acclaimed field biologist and college dean is ... Joseph Travis, dean of the College of Arts and Sciences ... researcher in the field of ecological genetics, has won the ... of the ASN in June, the award "is given to ...
... 2011 , the New York Academy of Sciences will ... of subspecialties, in addition to patients and caregivers, to ... of the clinical features, management, and treatment of Shwachman-Diamond ... affecting children and young adults. The clinical features ...
Cached Biology News:Plant pathologist finding Kansas wheat fields a molecular battleground this season 2FSU dean wins prestigious E.O. Wilson Naturalist Award 2FSU dean wins prestigious E.O. Wilson Naturalist Award 3New York Academy of Sciences hosts a conference on rare disease Shwachman-Diamond Syndrome 2
...
Normal human serum collected off the clot from healthy normal humans. Each donor unit is negative for anti-HIV 1&2, HIV-Ag, HCV, and HBsAg by FDA required tests...
Normal human AB serum, pooled...
sterile filtered, off the clot, all male donors, Total Protein: 4.5 to 8.5 g/dl...
Biology Products: